Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan 410011, China.
State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China; Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
J Diabetes Complications. 2018 Dec;32(12):1100-1104. doi: 10.1016/j.jdiacomp.2018.09.001. Epub 2018 Sep 7.
The aim of this study was to investigate the prospective association of circulating adipocyte fatty acid-binding protein (A-FABP) levels with the development of subclinical atherosclerosis in patients with type 2 diabetes in an 8-year prospective study.
A total of 170 patients with newly diagnosed type 2 diabetes were recruited in the study and 133 patients completed the follow-up of 8 years. Baseline plasma A-FABP levels were measured with enzyme-linked immunosorbent assays. The role of A-FABP in predicting the development of subclinical atherosclerosis over 8 years was analyzed using multiple logistic regression.
Of the 133 patients without subclinical atherosclerosis at baseline, a total of 100 had progressed to subclinical atherosclerosis over 8 years. Baseline A-FABP level was significantly higher in patients who had progressed to subclinical atherosclerosis at year 8 compared with ones who had not developed subclinical atherosclerosis after adjustment for sex (15.3 [12.1-23.2] versus 13.3 [10.0-18.9] ng/ml, P = 0.021). High baseline A-FABP level was an independent predictor for the development of subclinical atherosclerosis in patients with type 2 diabetes (odds ratio: 16.24, P = 0.022).
Circulating A-FABP levels predict the development of subclinical atherosclerosis in type 2 diabetes patients.
本研究旨在通过 8 年的前瞻性研究，探讨循环脂肪细胞脂肪酸结合蛋白（A-FABP）水平与 2 型糖尿病患者亚临床动脉粥样硬化发展的前瞻性关联。
共招募了 170 例新诊断的 2 型糖尿病患者，其中 133 例完成了 8 年的随访。采用酶联免疫吸附试验测定基线血浆 A-FABP 水平。采用多因素 logistic 回归分析 A-FABP 在预测 8 年内亚临床动脉粥样硬化发展中的作用。
在基线时无亚临床动脉粥样硬化的 133 例患者中，共有 100 例在 8 年内进展为亚临床动脉粥样硬化。与 8 年后未发生亚临床动脉粥样硬化的患者相比，进展为亚临床动脉粥样硬化的患者基线 A-FABP 水平明显升高（15.3 [12.1-23.2]ng/ml 比 13.3 [10.0-18.9]ng/ml，P=0.021）。高基线 A-FABP 水平是 2 型糖尿病患者发生亚临床动脉粥样硬化的独立预测因子（比值比：16.24，P=0.022）。
循环 A-FABP 水平可预测 2 型糖尿病患者亚临床动脉粥样硬化的发生。
